South Korea vs Middle income: Immunization, Hib3 (% of children ages 12-23 months)
South Korea
97.0%
in 2024
Middle income
77.1%
in 2024
South Korea rank
29th
Middle income rank
26th
Immunization, Hib3 (% of children ages 12-23 months) over time
- South Korea
- Middle income
How they compare
South Korea currently reports 97.0% against 77.1% in Middle income, a difference of 19.9%.
That makes South Korea's figure about 1.3 times Middle income's.
Across all 11 years both countries report, South Korea has been ahead every year.
South Korea ranks 29th and Middle income ranks 26th of 191 countries.
South Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | South Korea | Middle income | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 97.5% | 63.7% | 33.8% | South Korea |
| 2020s | 96.6% | 73.4% | 23.2% | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, South Korea or Middle income?
- South Korea, at 97.0% against 77.1% in Middle income as of 2024.
- What is the difference in immunization, hib3 between South Korea and Middle income?
- 19.9%, with South Korea ahead.
- How many years of comparable data are there for South Korea and Middle income?
- 11 years are reported by both, from 2014 to 2024.
- How do South Korea and Middle income rank globally for immunization, hib3?
- South Korea ranks 29th and Middle income ranks 26th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.